中恒集团：三芪颗粒获药物临床试验批准

Core Viewpoint - Zhongheng Group (600252) announced that its wholly-owned subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., received the approval notice for clinical trials of Sanqi Granules from the National Medical Products Administration on April 14, 2025 [1] Group 1 - Sanqi Granules is classified as a Class 1 innovative traditional Chinese medicine, representing an original research product [1] - The product is an optimized version of an in-hospital formulation, indicating prior human experience and a foundation of clinical efficacy and safety [1] - Preclinical pharmaceutical research and pharmacological toxicology studies have been completed for Sanqi Granules [1]